The Group announces that eight-year data for Opdivo (nivolumab) plus Yervoy (ipilimumab) continue to demonstrate the longest survival benefit over sunitinib reported in patients with previously untreated advanced or metastatic renal cell carcinoma.

Patients with previously untreated advanced or metastatic renal cell carcinoma treated with Opdivo and Yervoy experienced a 28% reduction in the risk of death compared with sunitinib eight years after the start of treatment, irrespective of risk group

The dual immunotherapy combination showed improved survival and durable responses compared with sunitinib in intermediate- and low-risk patients, as well as in all randomized patients.

Updated results from the phase 3 CheckMate -214 trial will be presented in an oral presentation at ASCO GU 2024.

' 'Not only are we seeing durable benefits over sunitinib in the primary endpoint population of intermediate- and low-risk patients, but also in the intention-to-treat population of the key secondary endpoint, showing that this dual-immunotherapy combination can potentially help patients achieve positive long-term outcomes, regardless of IMDC risk. ' said Nizar Tannir. M.D., F.A.C.P., Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center.

Copyright (c) 2024 CercleFinance.com. All rights reserved.